Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05813275
Other study ID # APC-APN-305
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 16, 2023
Est. completion date February 2025

Study information

Verified date April 2024
Source Apnimed
Contact Ron Farkis, MD
Phone 6175008880
Email Info@apnimed.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.


Recruitment information / eligibility

Status Recruiting
Enrollment 640
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years of age at the time of informed consent. 2. PSG criteria: AHI of >5; = 25% central or mixed apneas; and PLM arousal index =15 3. PROMIS-Fatigue: raw score =17 4. PAP intolerance or current PAP refusal. 5. BMI between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive. Exclusion Criteria: 1. Narcolepsy, restless leg syndrome, REM sleep behavior disorder 2. Insomnia disorder characterized by difficulty initiating or maintaining sleep, or use within the past month of sedative-hypnotics or other medication for the purpose of treating or avoiding insomnia symptoms. 3. Pierre Robin, Treacher Collins, or other craniofacial malformation syndrome, or grade =3 tonsillar hypertrophy. 4. Clinically significant cardiac disease, e.g., ventricular arrhythmia, untreated or unstable coronary artery disease, cardiac failure. Stable atrial arrhythmia is allowed. 5. Neuromuscular disorder (e.g., motor neuron disease, muscular dystrophy or myopathy, myasthenic syndrome); epilepsy; Parkinson, Alzheimer, or other neurodegenerative disease. Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AD109
Oral administration at bedtime
Placebo
Oral administration at bedtime

Locations

Country Name City State
Canada Canadian Sleep Consultants Calgary Alberta
Canada Medical Arts Health Research Kelowna British Columbia
Canada AMNDX Markham Ontario
Canada West Ottawa Sleep Centre Ottawa Ontario
Canada Canadian Phase Onward Inc. Toronto Ontario
Canada Sleep and Alertness Center Toronto Ontario
Canada Toronto Sleep Institute Toronto Ontario
United States Abington Neurological Associate Abington Pennsylvania
United States Orange County Research Institute Anaheim California
United States Atlanta Center for Medical Research, LLC Atlanta Georgia
United States FutureSearch Trials of Neurology Austin Texas
United States North County Neurology Associates Carlsbad California
United States Core Healthcare Group Cerritos California
United States Javara Inc - Tryon Medical Partners PLCC Charlotte North Carolina
United States Chattanooga Research & Medicine, PLLC Chattanooga Tennessee
United States Chicago Research Center Inc Chicago Illinois
United States Exalt Clinical Research Chula Vista California
United States CTI Clinical Research Center Cincinnati Ohio
United States Sleepp Management Institute (Intrepid) Cincinnati Ohio
United States UC Health Sleep Medicine Cincinnati Ohio
United States FutureSearch Trials of Dallas, LP Dallas Texas
United States Accel Research Sites DeLand Florida
United States Centennial Medical Group Elkridge Maryland
United States Lillestol Research LLC Fargo North Dakota
United States Tribe Clinical Research LL Greenville South Carolina
United States Research Centers of America, LLC Hollywood Florida
United States Lone Star Lung and Sleep Clinic Houston Texas
United States The Heights Hospital (HD Heights) Houston Texas
United States Huntsville Research Institute LLC Huntsville Texas
United States The University of Kansas Medical Center Kansas City Kansas
United States Canvas Clinical Research Lake Worth Florida
United States Revive Research Institute Lathrup Village Michigan
United States Florida Lung and Sleep Associates Lehigh Acres Florida
United States Preferred Research Partners, Inc. Little Rock Arkansas
United States Advanced ENT and Allergy Louisville Kentucky
United States Desert Clinical Research - CCT Research Mesa Arizona
United States Advanced Medical Research Institute Miami Florida
United States Clinical Site Partners Miami Florida
United States Catalina Research Institute Montclair California
United States Las Vegas Clinical Trials North Las Vegas Nevada
United States Clinical Neuroscience Solutions, Inc - Orlando Orlando Florida
United States Foothills Research Center - CCT Research Phoenix Arizona
United States Epic Medical Research Red Oak Texas
United States Probe Clinical Research Corporation Riverside California
United States OnSite Clinical Solutions LLC/Carolina Cardiology Associates P.A Rock Hill South Carolina
United States Element Research Group San Antonio Texas
United States Pacific Research Network San Diego California
United States Sleep Medicine Specialists of California San Ramon California
United States SDS Clinical Trials Inc. Santa Ana California
United States South Ogden Family Medicine / CCT Research South Ogden Utah
United States Georgia Neurology and Sleep Medicine Assoc Suwanee Georgia
United States JSV Clinical Research Study Inc Tampa Florida
United States Fiel Family Sports Medicine - PC CCT Research Tempe Arizona
United States Javarra Inc-Privia Medical Group Thomasville Georgia
United States Noble Clinical Research Tucson Arizona
United States Alabama Neurology & Sleep Medicine Tuscaloosa Alabama
United States Providere' Research Incorporated West Covina California
United States Neurology Specialists of Monmouth County West Long Branch New Jersey
United States PMG Research of Wilmington Wilmington North Carolina
United States Florida Pediatric Research Institute Winter Park Florida
United States Respiratory Specialists Wyomissing Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Apnimed

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of AD109 on airway obstruction in mild to sever OSA Proportion of participants with reduction in AHI (AHI, average number of events for every hour of sleep), measured by polysomnography 6 months
See also
  Status Clinical Trial Phase
Completed NCT05404438 - Mouth Breathing Habits Improvement Intervention N/A
Recruiting NCT05960175 - Impact of Patient Involvement in Alerts Management of Telemonitoring CPAP N/A
Completed NCT05075668 - Efficacy of HFNC as an Alternative to CPAP Therapy in Surgical Patients With Suspected Moderate to Severe OSA N/A
Completed NCT05881512 - Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea N/A
Completed NCT03336515 - Validity of a Vibrating Postural Device for the Treatment of Positional Obstructive Sleep Apnea (Postural) N/A
Not yet recruiting NCT05944965 - Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea Phase 1/Phase 2
Completed NCT02387476 - Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea N/A
Not yet recruiting NCT06058052 - Prevalence of OSA in Patients of ILD
Recruiting NCT03721445 - Could HRV be a Valuable Predictor for CPAP Adherence?
Completed NCT03172130 - Sham CPAP vs. Straight CPAP for Chronic Cough N/A
Recruiting NCT06320795 - Prospective Study for the Clinical Validation of the Soundi Wearable Medical Device N/A
Completed NCT01717339 - Sleep Apnea and Vascular Function N/A
Completed NCT00772044 - Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea Phase 4
Completed NCT02438137 - Dimethyl Fumarate for Obstructive Sleep Apnea N/A
Completed NCT01672606 - Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea N/A
Not yet recruiting NCT06110962 - Detecting Heart Rate, Respiration, and Sleep With the Sleeptracker-AI Under-mattress Monitor
Not yet recruiting NCT06400615 - Study That Tests AD109 in Patients Taking GLP-1 Drugs Phase 2
Completed NCT05060133 - Changes of the Upper Airway Volume After Orthognathic Surgery
Completed NCT03196583 - Efficacy of a Novel MAD in OSA N/A
Not yet recruiting NCT03933046 - The Association Between Sleep Duration and Sleep Disorders and Proteinuria in Children N/A